Literature DB >> 8497615

Early-enhancing pseudolesion in medial segment of left hepatic lobe detected with multisection dynamic MR.

K Ito1, T Choji, T Fujita, T Matsumoto, T Nakada, T Nakanishi.   

Abstract

On multisection dynamic magnetic resonance (MR) images obtained in the arterial-dominant phase, the authors have occasionally noted the presence of an early-enhancing pseudolesion, which is not a hypervascular tumor, in the medial segment of the left hepatic lobe. Multisection dynamic MR imaging was performed in 185 patients with suspected liver disease. A suspect early-enhancing pseudolesion was present in six of the 185 patients. In all six patients, the pseudolesion was located in the subcapsular portion adjacent to the porta hepatis in the medial segment of the left hepatic lobe. Corroborative and follow-up studies failed to demonstrate any evidence of a pathologic condition, therefore justifying the term "pseudolesion." Radiologists should be aware of the possibility of the presence of this early-enhancing pseudolesion in this typical location on multisection dynamic MR images, because such a finding may be misinterpreted as a true lesion.

Entities:  

Mesh:

Year:  1993        PMID: 8497615     DOI: 10.1148/radiology.187.3.8497615

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Differentiation between true focal liver lesions and pseudolesions in patients with fatty liver: evaluation of helical CT criteria.

Authors:  Philippe Soyer; Marc Sirol; Yann Fargeaudou; Florent Duchat; Lounis Hamzi; Mourad Boudiaf; Mounir Aout; Youcef Guerrache; Eric Vicaut; Roland Rymer
Journal:  Eur Radiol       Date:  2010-01-19       Impact factor: 5.315

2.  Hemodynamic changes of abdominal organs after CT colonography with transrectal administration of CO2: evaluation with early-phase contrast-enhanced dynamic CT.

Authors:  Kenichiro Ihara; Hideko Onoda; Masahiro Tanabe; Akihiko Kanki; Katsuyoshi Ito
Journal:  Jpn J Radiol       Date:  2021-05-08       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.